Treatment of psoriasis with retinoids: Present status

Cutis

Volumn 64, Issue 5, 1999, Pages 347-353

  Orfanos, C E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; ETRETINATE; KERATOLYTIC AGENT; RETINOID;

HUMAN; PSORIASIS; REVIEW;

ACITRETIN; ETRETINATE; HUMANS; KERATOLYTIC AGENTS; PSORIASIS; RETINOIDS;

EID: 0033227909     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Voorhees JJ, Orfanos CE: Oral retinoids. Broad spectrum dermatologic therapy for the 1980s. Arch Dermatol 117:418-421, 1981.
2. Gollnick HPM: Oral retinoids - efficacy and toxicity in psoriasis. Br J Dermatol 135(suppl 49): 6-17, 1996.
3. Olsen EA, Weed WW, Meyer CJ, Cobo LM: A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686, 1989.
4. Orfanos CE, Ehlert R, Gollnick H: The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34: 459-503, 1987.
5. Orfanos CE, Zouboulis CHC, Almond-Roesler B, Geilen CC: Current use and future potential role of retinoids in dermatology. Drugs 53: 358-388, 1997.
6. Orfanos CE: Retinoide: der neue Stand. Erhaltungstherapie, Resorptionsstörungen bei "non-responders", Interaktionen und Interferenzen mit Medikamenten, Behandlung von Kindern und Knochentoxizität, Acitretin und 13-cis-Acitretin. Hautarzt 40: 123-129, 1989.
7. Gronjoj Larsen F: Pharmacokinetics of etretinate and acitretin with special references to treatment of psoriasis. Acta Dermato-Venereol 190: 1-33, 1995.
8. Almond-Roesler B, Orfanos CE: Trans-Acitretin wird in Etretinat rückmetabolisiert. Bedeutung für die orale Retinoidtherapie. Hautarzt 47: 173-177, 1996.
9. Chou RC, Wyss R, Huselcon CA, Wiegand U-W: A potentially new metabolic pathway: ethyl esterification of acitretin. Xenobiotica 8: 993-1002, 1992.
10. Grønjøj Larsen F, Jakobsen P, Knudsen J, Weismann K, Kragballe K, et al.: Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 100: 623-627, 1993.
11. Vieira AV, Schneider WJ, Vieira PM: Retinoids: transport, metabolism, and mechanisms of action. J Endocrinol 146: 201-207, 1995.
12. Mangelsdorf DJ, Umesono K, Evans RM: The retinoid receptors. In, The retinoids. Biology, Chemistry, and Medicine (Sporn MB, Roberts AB, Goodman DS, eds ), ed 3, pp 319-349. New York: Raven Press, 1994.
13. Imcke E, Ruszczak SB, Mayer-da-Silva A, et al.: Cultivation of human dermal microvascular endothelial cells in vitro: immunocytochemical and ultrastructural characterization and effect of treatment with three synthetic retinoids. Arch Dermatol Res 283: 149-157, 1991.
14. Bécherel P-A, Mossalayi MD, Le Goff L, et al.: Mechanism of anti-inflammatory action of retinoids on keratinocytes. Lancet 344: 1570-1571, 1994.
15. Gollnick H, Bauer R, Brindley CJ, et al.: Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 19: 458-468, 1988.
16. Gollnick H, Zaun H, Ruzicka T, et al.: Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Eur J Dermatol 3: 442-446, 1993.
17. Lauharanta J, Geiger J-M: A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 121: 107-112, 1989.
18. Lowe NJ, Prystowsky JH, Bourget T, et al.: Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 24: 591-594, 1991.
19. Gollnick HPM, Orfanos CE: Clinical efficacy of etretinate and acitretin. European experience. In, Psoriasis (Roenigk HH, Maibach HI, eds), pp 725-748. New York: Marcel Dekker, 1991.
20. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ: Food increases the bioavailability of acitretin. J Clin Pharmacol 28: 1051-1055, 1988.
21. Simpson KR, Rosenbach A, Lowe NJ: Etretinate for retinoid-responsive dermatoses: further observations of long-term therapy. J Dermatol Treat 4: 179-182, 1993.
22. Lassus A, Geiger JM: Acitretin and etretinate in the treatment of palmoplantar pusrulosis: a double-blind comparative trial. Br J Dermatol 119: 755-759, 1988.
23. Orfanos CE, Lands E, Bloch PH: Traitément du psoriasis pustuleux par un nouveaux rétinoide aromatique (Ro 10-9359). Ann Dermatol Vénéreol 103: 807-811, 1978.
24. Saurat J-H, Geiger J-M, Amblard P, Beani JC, Boulanger A, Claudy A, et al.: Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177: 218-224, 1988.
25. Tanew A, Guggenbichler A, Hönigsmann H, Geiger J-M, Fritsch P: Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 25: 682-684, 1991.
26. Hartmann D, Mosberg H, Weber W: Lack of effect of acitretin on the hypoprothrombinemic action of phenprocumon in healthy volunteers. Dermatologica 178: 33-36, 1989.
27. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ: Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20: 1088-1093, 1989.
28. Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB: Fish oil supplementation results in decreased hypertrigliceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. J Am Acad Dermatol 19: 76-82, 1988.
29. Vahlquist C, Olsson AG, Lindholm A, Vahlquist A: Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients: results of a double-blind cross-over study. Acta Dermato Venereol (Stockh) 75: 377-380, 1995.
30. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC: Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 131: 1263-1267, 1995.
31. Geiger J-M, Baudin M, Saurat J-H: Teratogenic risk with etretinate and acitretin treatment. Dermatology 189: 109-116, 1994.
32. Lammer EJ, Chen DT, Hoar RM, et al.: Retinoic acid embryopathy. N Engl J Med 313: 837-841, 1985.
33. Lambert WE, De Leenheer AP, De Bersaques JP, Kint A: Persistent etretinate levels in plasma after changing the therapy to acitretin. Arch Dermatol Res 282: 343-344, 1990.
34. Rollmann O, Phil-Lundin I: Acitretin excretion into human breast milk. Acta Dermato-Venereol (Stockh) 70: 487-490, 1990.
35. Halkier-Sörensen L, Laurberg G, Andersen J: Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 16: 999-1006, 1987.
36. Hohl D, Pelloni F, Sigg C, Gilardi S, Jung T: A prospective study of skeletal changes during short-term acitretin therapy. Dermatology 185: 23-26, 1992.
37. Paige DG, Judge MR, Shaw DG, Atherton DJ, Harper JI: Bone changes and their significance in children with ichthyosis on long-term etretinate therapy. Br J Dermatol 127: 387-391, 1992.
38. Glover MT, Peters AM, Atherton DJ. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol 116: 609-614, 1987.
39. Chandraratna RAS: Tazarotene - first of a new generation of receptor-selective retinoids. Br J Dermatol 135: 18-25, 1996.
40. Foster RH, Brogden RN, Benfield P: Tazarotene. Drugs 55: 705-711, 1998.
41. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, et al.: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 134: 57-60, 1998.
42. Orfanos CE, Schmidt HW, Marhle G, Gartmann H, Lever WF: Retinoic acid in psoriasis: its value for topical therapy with and without corticosteroids. Clinical, histological and electron microscopical studies on forty-four hospitalized patients with extensive psoriasis. Br J Dermatol 88: 167-182, 1973.